David A. Siegel Innate Pharma Sa Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding IPHA
# of Institutions
10Shares Held
254KCall Options Held
0Put Options Held
0-
Exchange Traded Concepts, LLC113KShares$219,3550.01% of portfolio
-
Optiver Holding B.V. Amsterdam, P770.6KShares$136,8940.01% of portfolio
-
Morgan Stanley New York, NY44.1KShares$85,6000.0% of portfolio
-
Jane Street Group, LLC New York, NY14.6KShares$28,2340.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny10.6KShares$20,5230.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $155M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...